PROCESSING OF HCG IN NORMAL AND ABNORMAL PREGNANCIES
Project Number5R01HD035654-04
Former Number5R01HD035654-02
Contact PI/Project LeaderCOLE, LAURENCE ANTHONY
Awardee OrganizationUNIVERSITY OF NEW MEXICO
Description
Abstract Text
Preliminary studies in our laboratory are consistent with a relationship between hyperglycosylation (additional antennae and fucose residues on N-linked oligosaccharides) and nicking or cleavage of hCG. Other preliminary studies indicate the structural instability and diminished biological activity of hyperglycosylated and of nicked hCG molecules, and how they may be the source of free beta-subunit in the circulation and beta-core fragment in urine samples. Papers have been published showing raised hCG levels, and raised proportions of free beta-subunit and beta-core fragment levels in serum or urine samples from patients with trophoblast disease, hyperemesisgravidarum, or Down syndrome pregnancies. It is our hypothesis these raised levels arise from the hyperglycosylation of hCG, through pathways involving nicking, ineffectual autocrine control of hCG production, and dissociation to nicked free beta-subunit, and degradation to beta-core fragment. Other pathways raise levels of hCG and lower the proportions of hyperglycosylated hCG in patients with preeclampsia. Four sets of experiments are proposed to test this hypothesis and investigate the clinical ramification of the observations in normal and abnormal pregnancies. Studies are proposed to confirm and compare the levels of hCG, free beta-subunit and beta-core fragment in 1140 sets of parallel serum and urine samples from normal and abnormal pregnancies (Aim 1A); and to use the parallel serum and urine samples to investigate the clinical use of two new immunoassays that specifically measure hyperglycosylated hCG and nicked hCG, and their potential uses in screening for Down syndrome and preeclampsia (Aim 1B). Basic science studies are proposed to purify hCG from normal first, second and third trimester pregnancy urine samples, and preeclampsia, hyperemesis trophoblast disease and Down syndrome pregnancy urine samples (3 each) and compare the extents and sites of nicking, and the type, amounts and locations of hyperglycosylated N-linked oligosaccharides (Aim 2). Further studies are planned to investigate the hyperglycosylation- nicking relationship by comparing normal and hyperglycosylated hCG as substrates for nicking enzymes (Aim 3); and to examine the biological activities of the 21 purified normal and abnormal pregnancy molecules, and to determine their ability abilities to feedback through to the placenta and control hCG synthesis (Aim 4).
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Downs syndrome biomarker blood chemistry carbohydrate structure chorionic gonadotropin clinical research diagnosis design /evaluation female glycoprotein structure glycosylation hormone regulation /control mechanism human pregnant subject immunologic assay /test peptide hormone metabolism preeclampsia pregnancy disorder prenatal diagnosis protein purification protein sequence protein structure function tissue /cell culture urinalysis women's health
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
868853094
UEI
F6XLTRUQJEN4
Project Start Date
01-January-1999
Project End Date
31-December-2003
Budget Start Date
01-January-2001
Budget End Date
31-December-2003
Project Funding Information for 2001
Total Funding
$305,941
Direct Costs
$208,123
Indirect Costs
$97,818
Year
Funding IC
FY Total Cost by IC
2001
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$305,941
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01HD035654-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HD035654-04
Patents
No Patents information available for 5R01HD035654-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HD035654-04
Clinical Studies
No Clinical Studies information available for 5R01HD035654-04
News and More
Related News Releases
No news release information available for 5R01HD035654-04
History
No Historical information available for 5R01HD035654-04
Similar Projects
No Similar Projects information available for 5R01HD035654-04